<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117477</article-id><article-id pub-id-type="publisher-id">ACM-44226</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_39745971.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  左西孟旦在I型心肾综合征的应用
  Application of Levosimendan in Type I Cardiorenal Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>梓恒</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪花</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院急诊科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3283</fpage><lpage>3287</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  急性心脏病可伴随缺血性或非缺血性心脏病常出现急性肾损伤，而急性肾损伤是预后不良的独立危险因素，因此在治疗过程中，往往需要关注肾功能的变化。这也使病情更加复杂化，近几年来，左西孟旦作为一种不增加心肌耗氧的钙增敏剂应运而生。根据许多研究，它已被认为在心力衰竭的治疗中，具有一定肾脏保护功能。随着左西孟旦在其他急性心脏病伴心肾综合征中的运用，逐渐发现还有其他的有助于病情改善的作用。本文综述了目前为止关于左西孟旦在I型心肾综合征中的作用和疗效评价的研究报道，旨在能更加全面地认识该药物在I型心肾综合征中的作用并为进一步挖掘其潜能提供思路。
   Acute heart disease is associated with ischemic or non-ischemic heart disease, and acute kidney injury is an independent risk factor for poor prognosis. Therefore, changes in renal function often need to be paid attention to in the treatment process. This also makes the disease more complicated. In recent years, levosimendan has emerged as a calcium sensitization agent that does not increase the oxygen consumption of the heart muscle. According to many studies, it has been suggested to have some renal protection in the treatment of heart failure. With the use of levosimendan in other acute heart diseases with cardiorenal syndrome, other beneficial effects have been discovered. This paper reviews the current reports on the mechanism of action and efficacy evaluation of levosimendan in type I cardiorenal syndrome, aiming at a more comprehensive understanding of the role of levosimendan in parabolic cardiorenal syndrome and providing ideas for further exploration of its potential.
 
</p></abstract><kwd-group><kwd>左西孟旦，心肾综合征，急性肾损伤, Levosimendan</kwd><kwd> Cardiorenal Syndrome</kwd><kwd> Acute Kidney Injury</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>急性心脏病可伴随缺血性或非缺血性心脏病常出现急性肾损伤，而急性肾损伤是预后不良的独立危险因素，因此在治疗过程中，往往需要关注肾功能的变化。这也使病情更加复杂化，近几年来，左西孟旦作为一种不增加心肌耗氧的钙增敏剂应运而生。根据许多研究，它已被认为在心力衰竭的治疗中，具有一定肾脏保护功能。随着左西孟旦在其他急性心脏病伴心肾综合征中的运用，逐渐发现还有其他的有助于病情改善的作用。本文综述了目前为止关于左西孟旦在I型心肾综合征中的作用和疗效评价的研究报道，旨在能更加全面地认识该药物在I型心肾综合征中的作用并为进一步挖掘其潜能提供思路。</p></sec><sec id="s2"><title>关键词</title><p>左西孟旦，心肾综合征，急性肾损伤</p></sec><sec id="s3"><title>Application of Levosimendan in Type I Cardiorenal Syndrome<sup> </sup></title><p>Ziheng Wu<sup>*</sup>, Xuehua Zhang<sup>#</sup></p><p>Emergency Department, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/58-1572419x4_hanspub.png?20210729084436888" /></p><p>Received: Jun. 26<sup>th</sup>, 2021; accepted: Jul. 19<sup>th</sup>, 2021; published: Jul. 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/58-1572419x5_hanspub.png?20210729084436888" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Acute heart disease is associated with ischemic or non-ischemic heart disease, and acute kidney injury is an independent risk factor for poor prognosis. Therefore, changes in renal function often need to be paid attention to in the treatment process. This also makes the disease more complicated. In recent years, levosimendan has emerged as a calcium sensitization agent that does not increase the oxygen consumption of the heart muscle. According to many studies, it has been suggested to have some renal protection in the treatment of heart failure. With the use of levosimendan in other acute heart diseases with cardiorenal syndrome, other beneficial effects have been discovered. This paper reviews the current reports on the mechanism of action and efficacy evaluation of levosimendan in type I cardiorenal syndrome, aiming at a more comprehensive understanding of the role of levosimendan in parabolic cardiorenal syndrome and providing ideas for further exploration of its potential.</p><p>Keywords:Levosimendan, Cardiorenal Syndrome, Acute Kidney Injury</p><disp-formula id="hanspub.44226-formula29"><graphic xlink:href="//html.hanspub.org/file/58-1572419x7_hanspub.png?20210729084436888"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/58-1572419x8_hanspub.png?20210729084436888" /> <img src="//html.hanspub.org/file/58-1572419x9_hanspub.png?20210729084436888" /></p></sec><sec id="s5"><title>1. 引言</title><p>心肾综合征(Cardiorenal Syndrome, CRS)是指当心脏和肾脏其中某一器官发生急、慢性功能异常从而导致另一器官急、慢性功能异常的综合征，其中出现心功能迅速恶化，导致急性肾损伤(Acute kidney injury, AKI)的一类，称为I型心肾综合征，它通常出现在急性心脏病如急性失代偿性心力衰竭(Acute decompensated heart failure, AdHF)，并可伴随缺血性(急性冠状动脉综合征，心脏手术并发症)或非缺血性心脏病(瓣膜病，肺栓塞) [<xref ref-type="bibr" rid="hanspub.44226-ref1">1</xref>]。这些疾病的常用药物治疗，包括抗血小板、抗凝、利尿、血管扩张剂、正性肌力支持等。而左西孟旦作为一种新型正性肌力药物，临床主要用于治疗AdHF。近些年已经出现许许多多的临床试验探讨了左西孟旦对于各类心血管疾病合并心肾综合征的疗效及安全性。本文分析现有的基础实验和临床实验，描述目前为止左西孟旦的相关作用及其对I型心肾综合征的研究的一些想法。</p></sec><sec id="s6"><title>2. 左西孟旦</title><sec id="s6_1"><title>2.1. 左西孟旦的作用机制</title><p>心肌肌丝的肌钙蛋白在心肌收缩中起关键作用，而肌钙蛋白C是三个肌钙蛋白亚基中的一个，作为钙离子操作的分子开关，控制着心脏收缩期和舒张期过程中心肌力的产生 [<xref ref-type="bibr" rid="hanspub.44226-ref2">2</xref>]。</p><p>左西孟旦的三大作用机制，其一是通过钙依赖作用结合到心肌肌钙蛋白C起作用，从而拥有正性肌力作用；其二是通过开启血管平滑肌细胞上的钾离子通道，使细胞膜发生超极化，达到舒张血管的作用；其三是通过开启心肌细胞上的钾离子通道，减少线粒体内钙积累和稳定线粒体内膜通透性，从而实现心肌缺血再灌注损伤中的保护作用 [<xref ref-type="bibr" rid="hanspub.44226-ref3">3</xref>]。所以左西孟旦可减少缺血再灌注损伤引起的心肌细胞坏死和凋亡，起到心脏保护作用。</p></sec><sec id="s6_2"><title>2.2. 左西孟旦的药代动力学</title><p>左西孟旦的药代动力学在临床治疗的剂量范围内成线性关系，血药浓度增长与给药剂量正相关 [<xref ref-type="bibr" rid="hanspub.44226-ref4">4</xref>]。在临床治疗中，初始负荷6~12 μg/kg，负荷时间大于10分钟，之后以0.05~0.2 μg/kg/min的剂量持续输注，对于急性失代偿性心力衰竭患者持续给药时间通常为24小时 [<xref ref-type="bibr" rid="hanspub.44226-ref5">5</xref>]。左西孟旦的分布容积约为0.2 L/kg，与血液中的血浆蛋白结合(主要是白蛋白)，血浆蛋白结合率约97%~98%，半衰期1~1.5小时，经肝脏代谢，尿液排泄。在左西孟旦的代谢过程中，大约5%的药物在大肠转化为代谢物OR-1855)，然后在肝脏乙酰化形成活性代谢物OR-1896。OR-1896的半衰期约为75~80小时，但血浆蛋白结合率仅为40%，在心力衰竭患者中，在24小时左西孟旦输注结束后约2天OR-1896达到峰值，并在随后的2周内从循环中移除 [<xref ref-type="bibr" rid="hanspub.44226-ref4">4</xref>]。</p></sec></sec><sec id="s7"><title>3. 左西孟旦对I型心肾综合征</title><sec id="s7_1"><title>3.1. 传统正性肌力药物治疗I型心肾综合征</title><p>治疗心肾综合征的一个主要目标是提高肾小球滤过率(glomerular filtration rate, GFR)。肾髓质对于肾缺血较为敏感，因为肾髓质具有高氧要求的钠重吸收过程，所以GFR的单独升高会损害对肾髓质氧合的伤害。而多巴酚丁胺等传统正性肌力药似乎诱导肾传入和传出小动脉的平衡血管舒张，从而增加肾血流量(renal blood flow, RBF)，同时保持恒定的肾小球滤过压，但是对GFR并没有明显的改变 [<xref ref-type="bibr" rid="hanspub.44226-ref6">6</xref>]。而这一结果与LIDO试验的结果一致，多巴酚丁胺未表现出改善GFR [<xref ref-type="bibr" rid="hanspub.44226-ref7">7</xref>]。</p></sec><sec id="s7_2"><title>3.2. 左西孟旦治疗I型心肾综合征</title><p>随机对照LIDO试验报道，与多巴酚丁胺相比，使用左西孟丹治疗肾功能几乎正常的患者，其肌酐水平显著降低9%；在中度肾损害患者中，与多巴酚丁胺输注相比，左西孟旦对eGFR有更强的影响，72小时时增加45% [<xref ref-type="bibr" rid="hanspub.44226-ref7">7</xref>]。同样，随机双盲实验PORTLAND研究在日常临床实践中评估了左西孟旦治疗AHF的有效性和安全性。在使用左西孟旦后，先前少尿的患者利尿情况迅速改善，血清肌酐水平持续下降5天 [<xref ref-type="bibr" rid="hanspub.44226-ref8">8</xref>]。这一结论在Lannemyr L的试验中左西孟旦和多巴酚丁胺组的肾血流量同样增加(分别为22%和26%)，组间无显著差异。左西孟旦组肾小球滤过率增加22%，而多巴酚丁胺组肾小球滤过率保持不变。左西孟旦对滤过率无影响，多巴酚丁胺使滤过率降低17% [<xref ref-type="bibr" rid="hanspub.44226-ref9">9</xref>]。</p></sec><sec id="s7_3"><title>3.3. 左西孟旦治疗I型心肾综合征时的临床疗效评价</title><sec id="s7_3_1"><title>3.3.1. 心脏术后</title><p>根据相关报道，左西孟旦是唯一与生存改善相关的药物 [<xref ref-type="bibr" rid="hanspub.44226-ref10">10</xref>]。Zhao-Zhuo Niu等分析了5个随机试验中529例患者的数据(264例接受左西孟旦，265例对照组)，在这些研究中，有4个研究在冠状动脉搭桥术(Coronary artery bypass grafting, CABG)和体外循环(Cardiopulmonary bypass, CPB)中使用左西孟旦，而1个研究在心脏瓣膜或联合心脏瓣膜和冠状动脉搭桥术中使用左西孟旦。分析表明，使用左西孟旦与较低的AKI发生率相关[25/264 (占左西孟旦组9.5%) vs. 51/265 (占对照组19.2%)；OR = 0.44 (0.22~0.85)，效应P = 0.02，异质性P = 0.22，I<sup>2</sup> = 30%，包括529例患者和5项研究] [<xref ref-type="bibr" rid="hanspub.44226-ref11">11</xref>]。这一分析表明左西孟旦可能减少成人心脏手术患者的肾损伤。需要更多的前瞻性随机研究来进一步证明左西孟旦在心脏手术中对肾保护的益处。</p></sec><sec id="s7_3_2"><title>3.3.2. 心力衰竭</title><p>心力衰竭是一种累及肾、肺、肝的全身性综合征，对预后影响很大，心血管药物对非心脏器官的作用尤为重要。关于左西孟旦的肾脏保护作用的证据已经在相关的临床前实验有报告。有人提出左西孟旦可引起选择性肾小球传入小动脉血管舒张，从而改善肾脏滤过 [<xref ref-type="bibr" rid="hanspub.44226-ref9">9</xref>]。这一建议与LIDO试验的结果一致，在该试验中，左西孟丹治疗与肾小球滤过率(eGFR)的估计升高有关，而多巴酚丁胺治疗则没有，尽管两种药物都增加了心脏指数和尿量 [<xref ref-type="bibr" rid="hanspub.44226-ref7">7</xref>]。考虑到肾供氧与eGFR的增加成比例增加，eGFR的显著增强并不伴有肾氧合损害，尽管eGFR增强，但肾氧供需关系未受到损害。最近的一份报告显示，左西孟旦的eGFR增强作用与米力农并不相同 [<xref ref-type="bibr" rid="hanspub.44226-ref12">12</xref>]。</p></sec><sec id="s7_3_3"><title>3.3.3. 右心功能障碍及肺动脉高压</title><p>在右心室功能障碍和肺动脉高压患者中，肌酐的小幅升高是死亡率的独立预测因子；相反，在这些患者中，围手术期肾脏保存是很重要的。Guerrero-Orriach, J. L.等的研究是在RV功能障碍和肺动脉高压患者中进行的，发现在给予左西孟丹和手术后，三尖瓣环的直径和肺动脉压力减少；术后肺动脉压明显降低，由术后58 &#177; 18 (31.17~48.89) mmHg降至术后42 &#177; 19 (40~64.8) mmHg (P = 0.001)；右心室扩张从4.23 &#177; 0.7 (3.5~5.8) mm下降到3.45 &#177; 0.6 (2.5~4.8) mm (P = 0.044)；左西孟旦给药期间的总灌注量与往常一样；关于肾功能参数，基线肌酐为1.06 &#177; 0.24 (1.04~1.44) mg/dL，在48小时后上升至1.25 &#177; 0.37 (1.22~1.68) mg/dL，无显著差异(P = 0.05)；前24小时尿量为1.37 &#177; 0.3 (1.11~1.71) mL/kg/h，48小时后降至1.02 &#177; 0.23 (0.96~1.45) mL/kg/h，无患者需要肾替代治疗 [<xref ref-type="bibr" rid="hanspub.44226-ref13">13</xref>]。因此，可以想象，由于心室功能的改善而引起的肾静脉压的降低可能也有助于肾保护。</p></sec><sec id="s7_3_4"><title>3.3.4. 脓毒血症</title><p>临床前和小型临床试验显示左西孟丹对脓毒症患者的肾、有潜在的益处 [<xref ref-type="bibr" rid="hanspub.44226-ref14">14</xref>]。Gordon, A. C.等的试验选择了评估多器官功能障碍(包括心血管系统、呼吸系统、肾脏系统、肝脏系统、凝血系统五个器官系统)的日均序贯器官衰竭评分(SOFA, Sequential Organ Failure Assessment Score)作为主要结局，以充分评价左西孟旦的临床疗效和生物学效应；然而ICU住院期间的SOFA评分平均值，左西孟旦组为6.68 &#177; 3.96，安慰剂组为6.06 &#177; 3.89 (平均值差值为0.61；95%置信区间[CI]，−0.07~1.29)；并且在回归模型中调整ICU、年龄和APACHE II评分后，评分的平均差异为0.59 (95% CI，−0.02到1.20；P = 0.06)，没有证据表明左西孟旦对SOFA总分或评分的任何单项或任何其他临床结果有任何有益的影响 [<xref ref-type="bibr" rid="hanspub.44226-ref15">15</xref>]。但试验的样本量较小，且未与多巴胺等药物行横向对比，因此仍需进一步试验。</p></sec></sec></sec><sec id="s8"><title>4. 结论与展望</title><p>左西孟旦作为一款有别于传统正性肌力药物的钙增敏剂，对I型心肾综合征的治疗，尤其是心力衰竭患者的疗效也得到了肯定。但是，由于出现I型心肾综合征时病情的复杂性，左西孟旦能取得如此疗效绝不仅是因为其舒张肾小球传入小动脉的机制。随着研究人员的研究，逐渐发现左西孟旦运用于心脏术后、心力衰竭、右心功能障碍及肺动脉高压及脓毒血症等疾病的益处，但仍需大量前瞻性、随机、双盲的试验进一步证实。因此，对于左西孟旦治疗I型心肾综合征的机制以及临床效果，还需要更加深入的研究。</p><p>随着远程医疗和远程监控技术和科学的发展，在可预见的未来，左西孟旦在口服及短期静脉注射等方面的研究，可能是一种更适当的干预措施 [<xref ref-type="bibr" rid="hanspub.44226-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44226-ref17">17</xref>]。同时在儿童中的使用资料有限，在一个随机双盲研究在4岁以下的儿童接受心脏手术，患者接受左西孟旦明显心脏指数，降低肺动脉压力高于儿童接受多巴酚丁胺 [<xref ref-type="bibr" rid="hanspub.44226-ref18">18</xref>]。在不久的将来，有很强的理由对儿童使用左西孟旦进行适当的临床监管试验。</p></sec><sec id="s9"><title>文章引用</title><p>吴梓恒,张雪花. 左西孟旦在I型心肾综合征的应用Application of Levosimendan in Type I Cardiorenal Syndrome[J]. 临床医学进展, 2021, 11(07): 3283-3287. https://doi.org/10.12677/ACM.2021.117477</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44226-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ronco, C. and Di Lullo, L. (2014) Cardiorenal Syndrome. Heart Failure Clinics, 10, 251-280.  
&lt;br&gt;https://doi.org/10.1016/j.hfc.2013.12.003</mixed-citation></ref><ref id="hanspub.44226-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., et al. (2013) TNNI3K Is a Novel Mediator of Myofilament Function and Phosphorylates Cardiac Troponin I. Brazilian Journal of Medical and Biological Research, 46, 128-137. &lt;br&gt;https://doi.org/10.1590/1414-431X20122515</mixed-citation></ref><ref id="hanspub.44226-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bouchez, S., et al. (2018) Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. Cardiovascular Drugs and Therapy, 32, 617-624. &lt;br&gt;https://doi.org/10.1007/s10557-018-6838-2</mixed-citation></ref><ref id="hanspub.44226-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pierrakos, C., et al. (2014) Levosimendan in Critical Illness: A Literature Review. Journal of Clinical Medicine Research, 6, 75-85. &lt;br&gt;https://doi.org/10.14740/jocmr1702w</mixed-citation></ref><ref id="hanspub.44226-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Papp, Z., et al. (2020) Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Cardiac Failure Review, 6, e19.</mixed-citation></ref><ref id="hanspub.44226-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lannemyr, L., et al. (2018) Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients with Heart Failure and Renal Impairment: A Randomized Double-Blind Controlled Trial. Journal of the American Heart Association, 7, e008455. &lt;br&gt;https://doi.org/10.1161/JAHA.117.008455</mixed-citation></ref><ref id="hanspub.44226-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Follath, F., et al. (2002) Efficacy and Safety of Intravenous Levosimendan Compared with Dobutamine in Severe Low-Output Heart Failure (The LIDO Study): A Randomised Double-Blind Trial. The Lancet, 360, 196-202.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(02)09455-2</mixed-citation></ref><ref id="hanspub.44226-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Silva-Cardoso, J., et al. (2009) Effectiveness and Safety of Levosimendan in Clinical Practice. Revista Portuguesa de Cardiologia, 28, 143-154.</mixed-citation></ref><ref id="hanspub.44226-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lannemyr, L., et al. (2018) Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients with Heart Failure and Renal Impairment: A Randomized Double-Blind Controlled Trial. Journal of the American Heart Association, 7, e008455. &lt;br&gt;https://doi.org/10.1161/JAHA.117.008455</mixed-citation></ref><ref id="hanspub.44226-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Belletti, A., et al. (2015) The Effect of Inotropes and Vasopressors on Mortality: A Meta-Analysis of Randomized Clinical Trials. British Journal of Anaesthesia, 115, 656-675. &lt;br&gt;https://doi.org/10.1093/bja/aev284</mixed-citation></ref><ref id="hanspub.44226-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Niu, Z.Z., et al. (2014) Perioperative Levosimendan Therapy Is Associated with a Lower Incidence of Acute Kidney Injury after Cardiac Surgery: A Meta-Analysis. Journal of Cardiovascular Pharmacology, 63, 107-112.  
&lt;br&gt;https://doi.org/10.1097/FJC.0000000000000028</mixed-citation></ref><ref id="hanspub.44226-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lannemyr, L., et al. (2020) Effects of Milrinone on Renal Perfusion, Filtration and Oxygenation in Patients with Acute Heart Failure and Low Cardiac Output Early after Cardiac Surgery. Journal of Critical Care, 57, 225-230.  
&lt;br&gt;https://doi.org/10.1016/j.jcrc.2019.12.022</mixed-citation></ref><ref id="hanspub.44226-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Guerrero-Orriach, J.L., et al. (2016) Cardiac, Renal, and Neurological Benefits of Preoperative Levosimendan Administration in Patients with Right Ventricular Dysfunction and Pulmonary Hypertension Undergoing Cardiac Surgery: Evaluation with Two Biomarkers Neutrophil Gelatinase-Associated Lipocalin and Neuronal Enolase. Therapeutics and Clinical Risk Management, 12, 623-630. &lt;br&gt;https://doi.org/10.2147/TCRM.S102772</mixed-citation></ref><ref id="hanspub.44226-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Morelli, A., et al. (2005) Effects of Levosimendan on Systemic and Regional Hemodynamics in Septic Myocardial Depression. Intensive Care Medicine, 31, 638-644. &lt;br&gt;https://doi.org/10.1007/s00134-005-2619-z</mixed-citation></ref><ref id="hanspub.44226-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Gordon, A.C., et al. (2016) Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. The New England Journal of Medicine, 375, 1638-1648. &lt;br&gt;https://doi.org/10.1056/NEJMoa1609409</mixed-citation></ref><ref id="hanspub.44226-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wells, R., et al. (2018) Educate, Nurture, Advise, before Life Ends Comprehensive Heartcare for Patients and Caregivers (ENABLE CHF-PC): Study Protocol for a Randomized Controlled Trial. Trials, 19, 422.  
&lt;br&gt;https://doi.org/10.1186/s13063-018-2770-9</mixed-citation></ref><ref id="hanspub.44226-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Solomon, S.D., et al. (2007) Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients with Chronic Heart Failure. Circulation, 116, 1482-1487.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.107.696906</mixed-citation></ref><ref id="hanspub.44226-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ebade, A.A., Khalil, M.A. and Mohamed, A.K. (2013) Levosimendan Is Superior to Dobutamine as an Inodilator in the Treatment of Pulmonary Hypertension for Children Undergoing Cardiac Surgery. Journal of Anesthesia, 27, 334-339. &lt;br&gt;https://doi.org/10.1007/s00540-012-1537-9</mixed-citation></ref></ref-list></back></article>